Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Autologous stem cell therapy - Regeneration Biomedical

Drug Profile

Autologous stem cell therapy - Regeneration Biomedical

Alternative Names: Autologous adipose-derived stem cells - Regeneration Biomedical; RB-ADSC

Latest Information Update: 25 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Regeneration Biomedical
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Alzheimer's disease
  • Research Amyotrophic lateral sclerosis; Multiple sclerosis; Stroke; Traumatic brain injuries

Most Recent Events

  • 23 Apr 2024 Regeneration Biomedical plans a phase II trial for Multiple sclerosis, Parkinson’s disease, Traumatic brain injury and Amyotrophic lateral sclerosis
  • 14 Aug 2023 Phase-I clinical trials in Alzheimer's disease in USA (Intraventricular) (NCT05667649)
  • 18 Jan 2023 Regeneration Biomedical plans a phase I trial for Alzheimer disease (In adults, In the elderly) in January 2023 (NCT05667649)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top